Longeveron's Laromestrocel Findings in Alzheimer's Disease Chosen for Poster Presentation at CTAD 2025 Conference

Longeveron Inc. Presentation: Longeveron Inc. announced that their research on laromestrocel treatment for mild Alzheimer's disease has been selected for a poster presentation at the 18th Clinical Trials on Alzheimer’s Disease Conference (CTAD 2025) in San Diego, scheduled for December 1-4, 2025.

Research Significance: The findings from the CLEAR MIND study are expected to provide important insights into the mechanisms and clinical applications of cellular-based therapies for Alzheimer's disease, as stated by Joshua Hare, the company's Chief Science Officer.

About Laromestrocel: Laromestrocel (Lomecel-B) is a mesenchymal stem cell therapy derived from the bone marrow of young healthy donors, which may have anti-inflammatory and regenerative properties applicable to various rare and aging-related diseases.

Regulatory Designations: Longeveron is pursuing multiple indications for laromestrocel, including hypoplastic left heart syndrome and pediatric dilated cardiomyopathy, and has received several FDA designations to expedite its development.